Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis.
Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis.
复制标题
DOI：
10.1016/j.ajog.2009.04.005
复制
发表时间：
2009-06
影响因子：
9.8
通讯作者：
Romero R
中科院分区：
文献类型：
--
作者：
Conde-Agudelo A;Romero R
我们对随机对照试验进行了系统回顾和荟萃分析，以确定在妊娠34周前给予有早产风险的妇女硫酸镁是否可以降低其儿童脑瘫的风险。纳入了6项试验，涉及4796名妇女和5357名婴儿。口服硫酸镁可显著降低脑瘫的风险（相对风险[RR]，0.69; 95%置信区间[CI]，0.55 - 0.88]），中度或重度脑瘫（RR，0.64; 95% CI，0.44 - 0.92）和严重的粗大运动功能障碍（RR，0.60; 95% CI，0.43 - 0.83）。儿童总死亡率的风险没有总体差异（RR，1.01; 95% CI，0.89 - 1.14）。轻微的副作用在接受硫酸镁治疗的女性中更常见。总之，在妊娠34周前给予有分娩风险的妇女硫酸镁可降低脑瘫的风险。
We conducted a systematic review and meta-analysis of randomized controlled trials to determine whether magnesium sulfate administered to women at risk of preterm delivery before 34 weeks of gestation may reduce the risk of cerebral palsy in their children. Six trials involving 4796 women and 5357 infants were included. Antenatal magnesium sulfate was associated with a significant reduction in the risk of cerebral palsy (relative risk [RR], 0.69; 95% confidence interval [CI], 0.55–0.88]), moderate or severe cerebral palsy (RR, 0.64; 95% CI, 0.44–0.92), and substantial gross motor dysfunction (RR, 0.60; 95% CI, 0.43–0.83). There was no overall difference in the risk of total pediatric mortality (RR, 1.01; 95% CI, 0.89–1.14). Minor side effects were more frequent among women receiving magnesium sulfate. In conclusion, magnesium sulfate administered to women at risk of delivery before 34 weeks of gestation reduces the risk of cerebral palsy.
登录
查看更多内容
影响因子：
9.8
作者：
Mittendorf, R;Dambrosia, J;Tomich, PG
通讯作者：
Tomich, PG
影响因子：
9.8
作者：
Hayes, Edward;Moroz, Leslie;Baxter, Jason
通讯作者：
Baxter, Jason
影响因子：
1.9
作者：
Jensen, FE
通讯作者：
Jensen, FE
影响因子：
120.7
作者：
Crowther, CA;Hiller, JE;Haslam, RR
通讯作者：
Haslam, RR
影响因子：
2.9
作者：
Golan, H;Kashtutsky, I;Huleihel, M
通讯作者：
Huleihel, M